Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The primary endpoint is dystrophin protein levels, and the trial is also ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

With this circuit, CEA-Leti demonstrated 4- and 16-point QAM, that increases the possible number of multiplexed devices by ...

Cash Position: As of December 31, 2024, Fractyl had approximately $67.5 million in cash and cash equivalents. Based on current development plans, the Company believes existing cash and cash ...

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics has announced a significant restructuring, reducing its ...